NextCell Pharma

Since its inception in August 2015, Cellaviva has garnered a growing customer base each year, reflecting increasing awareness and demand for stem cell preservation services. This growth trajectory has positioned Cellaviva to successfully operate as a separate limited company effective September 1, 2024, while remaining a wholly owned subsidiary of NextCell Pharma AB.

Incoming CEO of Cellaviva Sofie Falk Jansson will outline her vision and strategic plans for the company's future in a presentation scheduled for 09:00 today, Wednesday, June 5. The presentation will be available for live streaming and for later viewing via the provided link:

https://www.redeye.se/events/1014540/investor-update-nextcell-pharma